Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design-Reference-Cited by-同舟云学术

Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design

Published:2022-11 Issue:5 Volume:77 Page:1237-1245
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Allen Alina M.^ORCID,Therneau Terry M.,Ahmed Omar T.^ORCID,Gidener Tolga^ORCID,Mara Kristin C.^ORCID,Larson Joseph J.^ORCID,Canning Rachel E.,Benson Joanne T.,Kamath Patrick S.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

National Institute on Aging

Publisher

Elsevier BV

Subject

Hepatology

Reference26 articles.

1. Endpoints and clinical trial design for nonalcoholic steatohepatitis;Sanyal;Hepatology,2011

2. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD;Rinella;Hepatology,2019

3. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort;Harrison;J Hepatol,2021

4. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials;Sanyal;Hepatology,2019

5. Prospective study of outcomes in adults with nonalcoholic fatty liver disease;Sanyal;N Engl J Med,2021

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

2. A landscape of liver cirrhosis and transplantation in Mexico: changing leading causes and transplant as response;Annals of Hepatology;2024-09

3. Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29‐year follow‐up;Hepatology Research;2024-08-19

4. Systematic review and meta-analysis of biomarkers predicting decompensation in patients with compensated cirrhosis;BMJ Open Gastroenterology;2024-08

5. A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease;Diabetes & Metabolism Journal;2024-07-31